To include your compound in the COVID-19 Resource Center, submit it here.

Merck prices Remicade biosimilar

Merck & Co. Inc. (NYSE:MRK) launched Renflexis infliximab-abda, its biosimilar of autoimmune drug Remicade infliximab from Johnson

Read the full 178 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE